ICER Misses the Numbers That Matter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
Categorized in: Analysis
Recent Blog Posts
Hidden Co-Pay Programs Blindside Patients
September 16, 2021
The Urgent Need to Address Urology Health
September 14, 2021
New Federal Policy Could Limit Non-Opioid Pain Treatments
September 10, 2021